Reluctance to enroll pediatric subjects in clinical trials has left gaps in information about dosing, safety, and efficacy of medications. Pharmacotherapeutic information for pediatric patients may be available for only a small range of ages and may be deficient, as children respond differently as they grow and mature from prematurity to adolescence. Current regulations, however, require early planning for the participation of children in drug development, as pediatric plans must be submitted at the end of phase 1 (European Union) or the end of phase 2 (United States). These plans are extensive, outlining planned studies, subjects to be enrolled, dose and dosage form justification, planned observations, and statistical analysis as well as planned modeling, simulation, and extrapolation analyses. The extent to which efficacy information in adults can be extrapolated to children depends on how similar the disease is in adults and each of the 5 pediatric age groups. Extrapolation may not be possible for conditions that do not occur in adults, requiring a complete development plan in adults, or extrapolation may be complete because of similar pathology and response to treatment. Pharmacokinetic and safety information cannot be extrapolated and must be collected in children of all ages, unless a waiver is granted. Physiologically based pharmacokinetic modeling, optimal design, population pharmacokinetics, and scavenged samples are all examples of new methodologies being used to study pediatric therapeutics. Clinicaltrials.gov and EU Clinical Trials registry are good sources of results of pediatric trials, although sponsors are also working toward prompt publication of study results in peer-reviewed journals.
It is not enough to simply tailor information available in adults to fit children. In the not-too-distant past, the use of Clark's rule and other formulae assumed children were small or young adults and scaled accordingly. 1 Doses for children were determined by multiplying the adult dose by the ratio of the child's weight to 150 pounds, for example. Studies to verify that doses so calculated were appropriate, safe, and effective were rarely conducted, in part because of the hesitancy to subject children to the demands of participation in clinical trials. Information about the stability, palatability, or acceptability of either the commercially available or extemporaneously prepared dosage forms was limited. Unfortunately, we have learned from therapeutic misadventure that pediatric-specific pharmacokinetic, safety, and efficacy data must be collected across the age and developmental spectrum so that clinicians can use medication optimally and avoid potentially severe adverse reactions. It is useful to consider an example to understand why pediatric subjects must be included in drug development. Chloramphenicol at doses of 100 mg/kg/day in divided doses was administered to neonates to treat or prevent infections in hospital nurseries. 2 Cases were reported of babies who had been treated for 3 or 4 days and were then observed to have abdominal distention with or without emesis, progressive pallid cyanosis, and vasomotor collapse, frequently accompanied by irregular respiration and who sometimes died with a few hours of onset of distress. The collection of symptoms was referred to as gray syndrome because of the ashen appearance of the skin. Assay of 200-μL blood samples, collected using finger-and heel-sticks, in affected infants showed their chloramphenicol concentrations to be unusually high. A series of focused clinical studies subsequently conducted in groups of 3 to 5 patients showed greatly prolonged half-lives (26 hours) in the very young children who were 1 to 2 days of age, compared with half-lives of 10 hours in babies who were 10 to 16 days of age. Ultimately, it was determined that slow conversion of chloramphenicol to metabolites and immature renal tubular excretion were likely responsible for the high concentrations. It was subsequently recommended that full-term infants receive 50 mg/kg/day and premature infants receive 25 mg/kg/day for the first week of life. The report summarizing the investigation, 2 published almost 60 years ago, encapsulates solutions to many of the S49 challenges of determining the best dose in young infants and even recommends the use of therapeutic drug monitoring for prolonged therapy.
It is now expected that medications come to market with directions for safe and effective use for patients of all ages or, alternatively, with statements that use in certain age ranges is not indicated for the approved indications. The directions, including contraindications and cautions, should be based on data collected in appropriately designed studies or robust documentation from epidemiological and toxicology studies. It is unfortunate that previous hesitancy to include children in clinical trials has resulted in gaps in the information available. Current drug development practices will hopefully make these deficiencies a thing of the past.
If we agree that all drugs that are developed should include children of all ages in clinical trials, let us first look at the drug development process in general. The potential list of pharmaceutical products that could be developed is almost endless. With thousands of diseases already described, continuing investigation into pathophysiology and identification of potential targets that could be manipulated to remediate or even cure and huge expansion of types of medicines that can be synthesized, there is a very long list of potential products that could be developed. Choices about which particular projects to advance are based on many factors. What therapeutic areas is the sponsor (company, manufacturer) of the development project already working in? It is easier to develop and market products to an existing community. What are the largest threats to public health or well-being that demand immediate attention and are likely to be supported by payers? Big, messy problems, such as Alzheimer's disease, may be solved more readily if there are many different sponsors working on the problem. Ongoing collaboration between academic researchers and private industry may also suggest emphasis on particular diseases.
Drug development begins with the end in mind, by making a mockup of what would be the ideal product labeling, including the indication, posology for all age groups, and the anticipated adverse reactions and precautions required for the most effective and safe use. With ideal product labeling outlined, a development plan is prepared that includes all the clinical and nonclinical studies required to provide information needed to support the specific language in the label. Each discipline, including discovery, clinical and nonclinical pharmacology, clinical and medical research, product formulation, toxicology, safety and epidemiology, among other functions, then expands its portion of the development plan to assess what is already known about the new chemical entity and what studies need to be performed to gather new information required either for the label itself or by other disciplines, so that they may perform their studies. Drug development is highly regulated, and so the data required for approval and, in turn, the studies required to provide much of the data are described in regulatory guidance statements and regulations, including the definition of a child.
Definition of Pediatric Age Groups
To be sure to gather data across the spectrum of pediatric development milestones, children are separated into 5 age groups, shown in Table 1 , and each age group must be considered in clinical development. Jurisdictions other than the United States 3 and the European Union 4 may have slightly different limits to the age ranges. In some development programs, there may be further subdivision of the 2-to 12-year age group of those younger than than 6 years and those at least 6 years old. Specific developmental milestones or conventions in medical practice may impose other restrictions on age. For example, tetracycline causes discoloration in developing teeth, and so is not recommended for children younger than 8 years old. 5 Hemophilia replacement products include children aged 12 years and older in the clinical trials of adults. 6 These age groups are not simply arbitrary divisions, but were developed to map onto stages of development that coincide with stages of maturity and milestones in development. Those who care for children recognize that there are different body systems influencing responses to pharmacotherapy and that these systems mature at different rates with added variability because of genetic, environmental, and social influences. 7 In addition to the obvious differences in weight between different age groups, there may also be differences in gastric pH, body composition, cytochrome P450 metabolic capacity, transporters, renal function, and hepatic function. For example, neonates have elevated intragastric pH and lower total volume of gastric secretions and immature conjugation and biliary function.
As therapeutic proteins become common, more will be learned about the ontogeny of target engagement and the elimination of monoclonal antibodies and fusion proteins, among others. 9 Children may also differ in the signs, symptoms, and pathology of diseases from children in different age groups or adults with similar disease. Some conditions are present at birth but may be delayed in manifesting pathology or may not respond to delayed treatment. By including children from each of these age categories in drug development, it is hoped that there will be adequate information available when a drug is first available on the market that will enable prescribers caring for children who may be maturing at different rates or who are smaller or larger than average to make good choices of doses to use.
Regulatory Guidance
Drug development has evolved such that inclusion of pediatric subjects in clinical development or, at a minimum, justification for why their involvement should be deferred or waived, is now a legal requirement. Most potential drug products are developed with the goal of global registration in mind, and so clinical development programs are planned to include elements that will satisfy the requirements of the major markets of the United States, Europe, and Japan and be in accordance with recommendations of the International Conference on Harmonisation. The key regulations and summary documents that provide a framework on how pediatric trials will be incorporated into clinical development include an alphabet soup of the Food, Drug and Cosmetics (FD&C) Act in the United States, the Food and Drug Administration Safety and Innovation Act, enacted in 2012, in which regulations originally approved in the Best Pharmaceuticals for Children Act (BPCA, 2002) and the Pediatric Research Equity Act (PREA, 2003) are included. Under the BPCA, sponsors of certain applications could obtain an additional 6 months of exclusivity if the sponsor submits information responding to a written request relating to the use of a drug in the pediatric population. All new medications including both drug and biological products are covered, although those with "orphan drug" designation are exempt from PREA regulations. Under the PREA, studies in pediatric patients are required for the indication that will be part of the new drug application unless granted a waiver or deferral. Waivers may be issued if the indication is not present in pediatrics, would not represent a significant therapeutic advantage, or poses a significant safety concern. Studies in rare diseases in pediatric subjects may also be eligible for the added incentive of a priority review voucher. Priority review vouchers may be transferred to other programs or sold to other sponsors. 10 Recently enacted legislation, the Pregnancy and Lactation Labeling Rule (PLLR), 11 which requires inclusion of information about the safety and pharmacokinetics of medications in pregnant and lactating women, is being implemented and will be largely completed by 2019. Studies of pregnant and lactating women are not part of drug development in children, and further discussion is beyond the scope of this article, but implementation of the PLLR provides important information about indirect dose administration to infants.
In the European Union, the Paediatric Regulation, which was enacted in 2007, resulted in the establishment of the Paediatric Committee (PDCO). The main responsibility of the PDCO is to determine the studies that sponsors must conduct in children as part of Paediatric Investigation Plans (PIPs). Because the PIP is rate limiting among these various legislations, clinical development plans for children will frequently begin with it. PIPs are the development plans describing the necessary data to be obtained through studies in children that will support the approval of a medicine, in the European Union. All applications for new medicines have to include the results of studies as described in an agreed-on PIP, unless the medicine is exempt because of a deferral or waiver. This requirement also applies when a sponsor wants to add a new indication, a new dosage form, or a route of administration for a medicine that is already approved. PIPs are rate limiting because they must be submitted to the PDCO no later than the end of the first phase 1 studies to assess pharmcokinetics in healthy adult subjects or patients. 12 They cannot be submitted after the initiation of pivotal trials, confirmatory, phase 3 trials, or trials conducted in children. It is important to note that the PIP must be agreed to by the European Medicines Agency (EMA) and must be fulfilled by the sponsor, unless an amendment is also agreed to by the EMA. Failure to complete the PIP to the satisfaction of the EMA will result in the sponsor being unable to file the application for the applicable new pharmaceutical product. 13 As noted previously, drug development in the United States is governed by the FD&C Act. One of the important milestones is the end of the phase 2 meeting. This meeting is held between the Food and Drug Administration (FDA) staff in the division that is reviewing the ongoing development and the sponsor. The meeting's purpose is to review the safety information that has been gathered in phase 1 and phase 2 studies, to evaluate the phase 3 plan and protocols, to identify additional information necessary to support a marketing application, and to review plans for studies in pediatric subjects. The initial pediatric study plan (iPSP) 14 describing these studies and/or justification for waivers and deferrals should be discussed with the FDA prior to the end of phase 2, and the PSP should be submitted within 60 days of the end of the phase 2 meeting. All marketing applications including a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration are required to submit an iPSP. iPSPs are reviewed by the Pediatric Review Committee, which will provide comments to the sponsor and ultimately issue the agreed initial PSP. The goal of the PSP process is to identify the necessary pediatric studies so that they can be completed prior to the submission of the new drug application or biologics license application in the case of biological therapeutics. For most sponsors, the iPSP is modeled on the PIP, which is required earlier in development.
Pediatric Studies
As noted previously, the road map to clinical development is the clinical plan, which is mapped out prior to administration of the very first dose to a human subject and is discussed with regulatory authorities in meetings prior to submission of the investigational new drug. The pediatric components may not be completely described at the pre-investigational new drug meeting, but as noted above, a PIP is required soon after the completion of the first-in-human study conducted and the iPSP prior to the end of phase 2, so there will be some vagueness in the initial plans, although the general outline of what studies will be performed in what age groups is expected. To determine the degree to which adult data may be used to support pediatric indications, an algorithm, shown in Figure 1 , that includes 4 key questions has been developed. Depending on the responses to the 4 questions, sponsors will be able to assess the extent of extrapolation possible for adult data. Neither pharmacokinetic nor safety observations can be extrapolated, and some data must be collected in every age group for which labeling is expected. As shown in Figure 2 , full extrapolation of efficacy information from adults means that only pharmacokinetic and safety data need to be collected in children, whereas partial extrapolation will mean a dose-finding study is required, and no extrapolation of information from adults means a sponsor is obliged to conduct separate dose-finding, safety, and efficacy studies in children. 15 It must be remembered that the 4 questions must be answered for each of the 5 pediatric age categories, and different answers to the questions may result in different degrees of extrapolation. For example, drugs used to treat infections are examples of medication for which full extrapolation is likely. 16 It is reasonable to assume that if similar concentrations of an antibiotic are achieved in children, whether neonates or adolescents, then the infection should respond in a similar way, but as described in the chloramphenicol example, pharmacokinetic data and safety data cannot be extrapolated and must be collected in all age groups.
An example of an indication that does not allow extrapolation is treatment for retinopathy of prematurity. 17 This condition does not occur in adults, and so all data supporting the safety, efficacy, and pharmacokinetics must be collected in children, specifically in those who are premature infants. Bevacizumab is an antivascular endothelial growth factor monoclonal antibody approved for the treatment of adults with metastatic colorectal cancer, nonsquamous, non-small cell lung cancer, metastatic breast cancer, and glioblastoma. After experimental use in adults with intraocular neovascular diseases without severe adverse reactions, investigators explored its use in combination with standard nonpharmacological therapy in an 8-week-old infant who was born at 25 weeks' gestation. 18 Then, a large prospective, randomized trial was conducted in 150 infants 33 to 35 weeks postmenstrual age, who were treated with 0.625 mg administered by intravitreal injection into each eye. 19 Efficacy was based on photographs taken at 54 weeks' postmenstrual age that were evaluated for recurrence of retinopathy, again unique to this condition. Because the dosing was empiric, additional trials are ongoing to assess the effectiveness of lower doses. 17 The safety profile of systemically administered bevacizumab was well described from studies in adults being treated for cancer but was not applicable to infants treated with intravitreal injections who would receive 1 or 2 doses in each affected eye, with minimal anticipated systemic availability.
In addition to medications developed with either no extrapolation or full extrapolation of efficacy from adults are intermediate cases, for which information obtained in adults can be supplemented with efficacy data from children. Adult to adolescent extrapolation is relatively common. 20 As noted above, in rare diseases, such as hemophilia, adolescents are enrolled in adult studies without distinction because of their age, 6 and for some conditions, such as migraine headache and schizophrenia, 15 there is a continuity of both disease and response to treatment between adults and pediatric populations. Adolescents are similar in size to adults and have mature physiology. Their quest for autonomy and potential lack of compliance may make participation in clinical trials challenging but is needed to validate assumptions of similar pharmacokinetics, safety, and efficacy. 21 Extrapolation of efficacy and response data from adults to children younger than 12 years of age may be more difficult than for adolescents and becomes progressively more difficult in the youngest age groups because of immature renal function and metabolic activity, differences in body composition, and challenges in drug administration. For some, a waiver is preferred because the disease does not manifest itself or the assessment of response is not possible, such as allergic conjunctivitis in children younger than 2 years of age, for example. 15 Onset of disease may be indicative of a different pathology than disease that usually occurs in adults. For example, congestive heart failure in children is more likely from congenital heart disease, whereas in adults, ischemic heart disease is the culprit. 15 Partial extrapolation is possible when there is uncertainty in the assumption that the disease and the response to treatment are similar in adults and children. Either a single, adequate, well-controlled trial proving efficacy in addition to safety and pharmacokinetics can be performed, or when there is less uncertainty, a study underpowered to demonstrate efficacy can be conducted. Juvenile rheumatoid arthritis (JRA) is an example of partial extrapolation as well as evolution of requirements as more children participate in clinical studies. 15 For symptomatic relief, when there was an extensive understanding of mechanism of action, extrapolation was permitted, or at least inclusion of different subtypes in the same study. For disease-modifying drugs, the FDA requires independent confirmation of efficacy in pediatric populations in each of the subtypes of JRA. 15 
General Study Considerations for Pediatric Subjects
The age range in a dedicated pediatric pharmacokinetic or pharmacokinetic/pharmacodynamic study should be consistent with the pediatric age range for the intended population of treatment. Clinical trials in pediatric populations are conducted in those individuals who stand to potentially benefit from the treatment. Healthy children participate in studies such as immunization trials against diseases that they might reasonably be expected to contract 22 or postapproval assessment of nutritional supplements. 23 Reasonably stable children with the target disease participate in clinical pharmacology studies as well as in clinical studies of medications used to treat diseases that occur only in children. 24 Legal regulations and social conventions assert that children lack the autonomy and life experience to judge the risk and benefit of participating in a clinical trial. Institutional review boards and ethics committees reviewing and approving studies being conducted in children must include adequately trained and experienced clinicians and researchers who are able to assess the risks and benefits on behalf of the vulnerable pediatric population. In addition to the consent to participate given by parents or guardians, it is also good practice to provide age-appropriate information about the clinical trial and obtain assent from the potential participants if their maturity and condition allow. Because there are fewer pediatric patients available to participate in clinical trials and because children are a vulnerable population, study-site selection is important to ensure that the clinical sites have the infrastructure in place to meet the protocol requirements, especially if special techniques or assessments are required. Fortunately, as pediatric studies have become a regular part of drug development, expertise is becoming more available. Sponsors have formed internal pediatric councils, among whose members are toxicologists, pathologists, clinical pharmacologists, formulators, assay specialists, statisticians, researchers, and clinicians with expertise in pediatric drug development. These councils review clinical development plans and study protocols prior to submission to regulatory authorities to ensure highquality pediatric development programs that are delivered in a timely fashion while attending to the safety of participants in the trials. In addition to internal pediatric councils, pediatric research networks have been expanded to include sponsors in addition to academic research centers. 25 Research networks improve the efficiency of drug development by providing education and certification for investigators that can be recognized by different sponsors. Through their experience, they can offer direction for improving trial design, 26 developing and validating standard processes for subject enrollment, dosing, collection of observations, including blood sampling, 27 and information about the natural history of disease, growth, and development. Networks can be organized to span different countries and regions to promote the highest standards of clinical research, including attention and support of pediatric subjects and their families to minimize the burdens of participating in clinical trials. Networks vary in their size, diseases, and populations of interest and funding sources. Examples of pediatric research networks are the Children's Oncology Group, 28 the European Network of Paediatric Research at the European Medicines Agency, the Pediatric Trials Network, 29 the Institute for Advanced Clinical Trials for Children, and the Paediatric Trials Network Australia.
The decision to conduct a study as an inpatient or an outpatient trial is based on considerations similar to those in adults and include the age of the child, the illness, the treatment required, the observations being made, and the location of staff and equipment. Studies of premature infants are typically inpatient studies. Children in stable condition may be able to participate as outpatients or with only a limited number of overnight stays. Accommodation must be made for parents or guardians who may need to stay with the child and provide transportation of the child to the research unit. Timing of the activities in studies must also consider school schedules and immunization schedules, which may make participation in trials difficult for some age groups.
Knowledge of the impact of coadministration of food with the study drugs is important in the design of clinical trials in children. 30 Healthy adult volunteers and many adult patients can tolerate administration in fasted conditions or administration with a standardized meal. It is difficult to be confident of compliance on the part of children. Infants and young children are fed 4 to 6 times daily, consuming breast milk, formula, or semisolid food, such as cereal, yogurt, and pureed vegetables, fruits, and meats. Children may refuse to consume standard meals or perhaps even food of any kind, particularly if they are feeling unwell. When the effect of food is either unknown or a source of variability in clinical response, it is important to collect information about the time and composition of the last meal consumed prior to dose administration to help to interpret the results. The effect of food on pharmacokinetics or efficacy and safety can also be incorporated into the study design by allowing children to consume one of several meals or remain fasting and noting their feeding status as a covariate. 31 The decision to include children of different races/ethnicities and sexes is made in a similar manner as in adults. No group of children with the target disease is excluded, but some diseases often genetically determined occur more commonly in boys, such as hemophilia; at some ages, such as apnea of prematurity; or predominately in some races, such as sickle cell disease. Cultural sensitivity is needed when enrolling girls who could potentially have achieved menarche, and older children who may be participating in sexual activity or illicit drug use. Thoughtful explanation of the testing necessary to protect the safety of the children, as well as the validity of the interpretation of the study results, is important to the conduct of the study. Beyond general considerations of designing clinical trials in children, 3 common elements, dose, observations, and analysis, require particular attention. These will now be considered in turn.
Pediatric Dose
To optimize the benefit:risk ratio in trials in patients, investigators try to avoid both ineffective doses and doses higher than required during dose-finding or pharmacokinetic studies and include only doses predicted to achieve concentrations that have been shown in nonclinical studies or simulations to be efficacious and tolerable. When the clearance of a drug can be predicted in children, then the dose required to achieve a target concentration can be calculated, albeit with sometimes large variability. Differences in volume of distribution must also be considered but are usually of concern only when dosing is intermittent or a particular target concentration must be achieved immediately on starting treatment.
The most common method of determining clearance in pediatric subjects is weight-based allometric scaling. Clearance is assumed to be a function of weight at three-quarters power. 32 However, because age-related maturation is not included in calculations, allometric scaling is not reliable for young children, especially those younger than 2 years, 7 because of continuing ongoing maturation of metabolic pathways. Segmented allometric models, which implement different exponents for different ages, have been developed to accommodate different age groups 33 and dosage forms such as extended-release tablets that support only limited flexibility in dosing. 34 Physiologically based pharmacokinetic (PBPK) models may be able to overcome some of the limitation of allometric scaling. PBPK models integrate physiologic information, such as age-specific blood flow, protein concentration, and enzyme and transporter ontogeny with pharmacokinetic parameters such as percent of dose eliminated by renal clearance or metabolized by particular pathways and can be used to predict the disposition in children of various levels of maturity. 35, 36 Advances in software, the increased availability of physiological and tissue distribution data have resulted in more frequent use of PBPK models for drugs in development. Models have been developed for both small molecules and biologics. Edington and colleagues 37 extended preexisting PBPK models for acetaminophen, alfentanil, morphine, theophylline, and levofloxacin to include data for children and evaluated the performance of the models in predicting pediatric plasma profiles. Eighty-three percent, 97%, and 87% of the predicted plasma concentrations, volumes of distribution, and elimination half-lives, respectively, were within 50% of values reported. PBPK models are then used to help to design dosing schemes, PK sampling times, and times for other observations in clinical trials in pediatric subjects. For example, sirolimus has not been investigated in children yunger than 13 years old, so Emoto and colleagues used PBPK methods to develop a model for sirolimus to make predictions for children aged 1 month to 2 years who were to be enrolled in a phase 2 efficacy and safety trial for treatment of vascular anomalies. 38 Regardless of the method used to select the doses to be evaluated in protocols, it is a best practice to include a maximum dose to avoid overdosing large or heavy children.
Dosage Forms
Important to accurate, precise, and consistent dose administration is the availability of an appropriate dosage form for the intended population. Although there are many different ways that medication can be administered and all can be adapted for different age groups, the most common route of administration is oral, and the most common oral dosage forms used in children are liquids and solids, including powders, sprinkles, dissolving tablets, minitablets, and tablets.
Discussion of dosage forms is an integral part of PIPs, and so each of the following must be described in the PIP document 4, 35 : the specific formulation, pharmaceutical form, strength and route of administration for each of the pediatric age groups, potential issues concerning excipients and their predicted exposures at the anticipated dose, administration of doses to the different pediatric age groups, including acceptability, use of administration devices, ability to mix with milk, formula, or food, precision of the dose delivery and/or accuracy of the dosage form for each of the pediatric age groups, and the anticipated time frame for development of the formulations and dosage forms. Dosage forms used with children must be palatable and must permit flexible dosing to accommodate reasonable precision over the large range of doses that are required. Use of dosing bands, by assigning children over a range of weights to the same dose, allows use of capsules or tablets that may be more stable to be used in cases in which some flexibility in dosing is permissable. 35, 40 The relative bioavailability between the different dosage forms must be known so that as children are switched, the required dosing is maintained. Stability information is also required for all dosage forms and understanding of the impact of excursions in temperature, such as when doses are not refrigerated. Dissolution testing, which is an important metric for the development of oral dosing forms, needs to be evaluated using a relevant dissolution media if the product will be used in very young children whose physiology differs from older children and adults. 41 Beyond oral formulations, differences between adults and children must also be considered. 42 For example, medications that are injected will require concentrations that are neither too potent, when it is difficult to accurately administer the very small doses required for premature infants, or too dilute, which would require large injection volumes that would not be tolerated for subcutaneous injection. There are many different ways of administering medication by aerosol that vary in the effectiveness in delivery as well as degree of cooperation required of the patient and skill in use by research staff. 43 Drugs administered as eye drops are also challenging for treating conditions in children. Because of the small volume administered, the concentration of active ingredients is high. The eye of a newborn is approximately two-thirds of the adult size and does not reach adult size until age 3 to 4 years. Ocular dosing is not weight or size adjusted, and so children may receive much higher doses than adults. 44 Protocols and supplementary dose administration instructions need to be clear so that the doses are administered as consistently and accurately as possible.
Observations
Technical challenges in collection, standardization, and interpretation have limited the use of potentially less invasive matrices 45 such as saliva, urine, and hair, and so blood samples are collected in almost every type of pediatric study in drug development, whether for assessment of safety, efficacy, or pharmacokinetics, even in critically ill and very small patients. To characterize pharmacokinetic parameters in individual subjects, conventional pharmacokinetic sampling requires 10 to 12 samples collected over a dosing interval in multipledose studies or more than 3 to 5 half-lives in singledose studies. A review 46 of guidelines on sampling permitted in pediatric studies reported a maximum cumulative volume of blood of 3-7 mL/kg collected over 8 weeks. Faced with the necessity of including baseline and end-of-study safety assessments of serum chemistry, hepatic, renal, and hematology values, pharmacokinetic sampling in young children and infants, by necessity, is sparse, representing only a subset of conventional sampling. Optimal sampling designs may be used in which blood samples are collected at the times that are most likely to provide information about the likely model 47 as well as times linked to particular safety or efficacy signals, such as likely peaks and troughs. Simulations of the anticipated concentration-time profiles are helpful to avoid sampling times that are likely to be uninformative because the concentrations fall below the limits of quantification of the assay.
In addition to minimizing the volume of blood collected, investigators must also minimize the number of collection times. Opportunistic study designs, also known as scavenged sampling, which schedule research sample collection to coincide with sample collection for routine laboratory draws, 48 may be used in studies in children. Authors have suggested that opportunistic study designs are useful for further investigation of medications that are already prescribed to children rather than investigational drug products. The decision to prescribe the medication is made outside the clinical trial, but once the order has been written, enrollment in the study occurs, with consent focused on the collection of extra blood volume to answer the research question. The limitations of varied timing and number of samples make opportunistic sampling strategies difficult to use in drug development.
Monitoring for safety and efficacy in pediatric subjects is incorporated into research protocols in much the same manner as for adults. Baseline assessment takes place prior to administration of the study drug to verify that subjects are eligible to enroll, do not have any exclusion characteristics, and will be able to cooperate with study assessments. For the study results to be meaningful, assessments must be age appropriate and capable of detecting safety signals unique to children, such as interference with growth 49 and development. Specific systems may be more (or less) tolerant of drug effect as a result of a combination of differences in physiology and body composition. For example, higher brain penetration of medications in neonates, both human and animal, may be the result of active transport systems evolved to transport nutrient and other molecules needed for development of the central nervous system, as well as differences in volume of distribution related to body composition, reduced blood plasma protein-binding capacity, and reduced renal flow.
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Data Analysis
Data analysis methods used for pediatric studies are similar to those used for adult studies. Because of the limited number of samples collected, individual determination of pharmacokinetic parameters for each subject may be only post hoc estimates based on a population pharmacokinetic model. Naive pooled estimates may also be used to determine pharmacokinetic parameters, 51 although care must be taken to normalize for dose administered and size of the sample of the subjects studied.
Disclosure/Publication of Study Results
Important to the protection of subjects who participate in clinical trials are the processes requiring quick, complete disclosure. All interventional studies conducted in the United States must be registered on the website www.clinicaltrials.gov. The clinicaltrials.gov information resource was initiated as a result of the Food and Drug Administration Modernization Act of 1997. The registry was established by the National Institutes of Health for experimental treatments for serious or life-threatening diseases or conditions and was initially intended to provide patients searching for available trials a central place to look. It was expanded in 2007 to require additional types of trials to be registered as well as reporting summary results, including adverse events. Under most circumstances for studies in children, results must be posted within 12 months of the date of final data collection for the prespecified primary outcome measures. 52 European regulations established Article 46 of Regulation (EC) 1901/2006, 53 under which studies, of products that are registered in the European Union, enrolling pediatric subjects must provide a completed clinical study report to the EMA within 6 months of study completion. The requirements apply to all studies with pediatric subjects, even if not included in a PIP. The EMA will in turn make all results available through the EU Clinical Trials Register (www.clinicaltrialsregister.eu).
Publication of study results in a peer-reviewed journal is the final step in making information available to the public. Guidelines 54 have been developed encouraging prompt and balanced reporting of all completed clinical trials, regardless of whether they were positive. Because of the difficulty in enrolling pediatric subjects, it is particularly important that these data be presented and made available to add to the literature. The primary publication is the initial publication of a clinical trial and should be submitted for publication ideally within 12 months (18 months at the latest) of the completion of the clinical trials. 54 Although data are not available specifically for trials of pediatric subjects or of clinical pharmacology studies, approximately 90% of studies registered at clinicaltrials.gov have been published. 55 
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Next Steps and Remaining Questions
With the inclusion of pediatric subjects as a standard part of clinical development, more data are being collected so that drug development in children has expanded far beyond simple description of a small group of heterogeneous subjects. Beyond studying children of all ages, the problem of the correct dose for obese 56 or underweight children is beginning to get attention. Perhaps more importantly, the advances that are being made to support drug development work in children, including in fragile newborns, can be extended to the study of other vulnerable populations such as pregnant and lactating women. 57 The goal of perfect pediatric posology may indeed be at hand.
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